TABLE 2.
Summary of studies for toxicities of HER-2 target drugs.
| ERBb2-Targeted drugs | Toxicities | References | |
|---|---|---|---|
| Monoclonal antibody | Trastuzumab | LVEF decreased, HF happened, Arrhythmia | Romond et al. (2012), Bayar et al. (2015), Serrano et al. (2015), Jacquinot et al. (2018), Nowsheen et al. (2018), Hussain et al. (2019), Keramida et al. (2019), Yoon et al. (2019), Upshaw et al. (2020) |
| Pertuzumab | Neutropenia and diarrhoea | van Ramshorst et al. (2016), Tan et al. (2021) | |
| Margetuximab | Diarrhoea, nausea, anaemia and pyrexia | Markham (2021) | |
| Antibody–drug conjugates | T-DM1 | Transient LVEF decreased | (Krop et al. (2014), Pondé et al. (1990), Perez et al. (2017), von Minckwitz et al. (2019) |
| DS-8201 | Anaemia, neutropenia, thrombocytopenia, leukopenia, and interstitial lung disease or pneumonia | Modi et al. (2020) | |
| Tyrosine kinase inhibitors | Lapatinib | Mild diarrhoea and rash | Bilancia et al. (2007), de Azambuja et al. (2014), Eiger et al. (2020) |
| Neratinib | Diarrhoea | Awada et al. (2016), Chan et al. (2016), Martin et al. (2017) | |
| Tucatinib | Diarrhoea and hepatotoxicity | Lee (2020), Shah et al. (2021) | |
LVEF, left ventricular ejection fraction; HF, heart failure; T-DM1, Trastuzumab emtansine; DS-8201, Trastuzumab deruxtecan.